Consensus Novartis AG

Equities

NOVN

CH0012005267

Market Closed - Swiss Exchange Other stock markets 11:31:48 2023-12-01 am EST			5-day change	1st Jan Change
85.38 ^CHF	+0.31%		-1.62%	+2.14%

Nov. 30	NOVARTIS AG : Deutsche Bank gives a Buy rating	ZD
Nov. 29	NOVARTIS : Oddo BHF confirms its recommendation after R&D day	CF

Evolution of the average Target Price on Novartis AG

Price target over the last 5 years

History : Analyst Recommendations

637abaea2004f6dc2f83de5.du5d_BJHcQXH6jeMVBJx76FkvuWknELLgZjrRoEPUHg.Dpg7lUImP0ujhmS8IFw-hfUc-a3A_TOqyvCBPPFQYz8TiWzKWHc0cbCFDw~57e0ad78ff62acfb91bf7663be23df26

Analyst Recommendations on Novartis AG

NOVARTIS AG : Deutsche Bank gives a Buy rating	Nov. 30	ZD
NOVARTIS : Oddo BHF confirms its recommendation after R&D day	Nov. 29	CF
NOVARTIS AG : Sell rating from Barclays	Nov. 29	ZD
NOVARTIS AG : Gets a Neutral rating from UBS	Nov. 28	ZD
NOVARTIS : price target maintained by Oddo BHF	Nov. 28	CF
NOVARTIS AG : Jefferies reaffirms its Buy rating	Nov. 28	ZD
NOVARTIS AG : Receives a Buy rating from Deutsche Bank	Nov. 27	ZD
Kepler Cheuvreux Lifts Price Target on Novartis, Maintains Buy Recommendation	Nov. 08	MT
NOVARTIS AG : Deutsche Bank remains its Buy rating	Oct. 26	ZD
Societe Generale Lowers Price Target on Novartis, Maintains Buy Recommendation	Oct. 25	MT
NOVARTIS : Healthy Q3; guidance upgraded ‘again’	Oct. 24
NOVARTIS AG : UBS remains Neutral	Oct. 24	ZD
NOVARTIS AG : Jefferies gives a Buy rating	Oct. 24	ZD
NOVARTIS AG : Barclays maintains a Sell rating	Oct. 23	ZD
Novartis to Navigate Patent Expirations After Concluding Simplification, Berenberg Says	Oct. 20	MT
NOVARTIS AG : Berenberg sticks Neutral	Oct. 19	ZD
Redburn Atlantic Lowers Price Target on Novartis, Maintains Neutral Recommendation	Oct. 13	MT
Stifel Lowers Price Target on Novartis, Maintains Buy Recommendation	Oct. 12	MT
NOVARTIS AG : Jefferies keeps its Buy rating	Oct. 11	ZD
DZ Bank Lowers Price Target on Novartis, Maintains Buy Recommendation	Oct. 10	MT
NOVARTIS AG : JP Morgan sticks Neutral	Oct. 05	ZD
NOVARTIS AG : Deutsche Bank gives a Buy rating	Oct. 05	ZD
NOVARTIS AG : Gets a Neutral rating from UBS	Oct. 04	ZD
Fitch Affirms Bausch Health, Bausch Health America's Ratings; Bausch + Lomb's Rating Maintained	Oct. 04	MT
NOVARTIS : Taking on board the Sandoz spin-off.	Oct. 04

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

98.09USD

Average target price

105.39USD

Spread / Average Target

+7.45%

High Price Target

124.68USD

Spread / Highest target

+27.11%

Low Price Target

83.80USD

Spread / Lowest Target

-14.56%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Novartis AG

DEUTSCHE BANK RESEARCH	Emmanuel Papadakis
BARCLAYS	Emily Field
UBS	Colin White
JEFFERIES	Peter Welford
Kepler Capital Markets
Societe Generale
alphavalue	Abhishek Raval
BERENBERG	Kerry Holford
Redburn
Stifel Nicolaus
DZ Bank
JPMORGAN	Richard Vosser
BNP Paribas
MORGAN STANLEY	Mark Purcell
Barrington Research
Credit Suisse
International Strategy & Investment Group
Morningstar
ODDO BHF
GOLDMAN SACHS	Keyur Parekh
DA Davidson
Zacks Equity Research
Bank of America Securities/Merrill Lynch
BERNSTEIN RESEARCH	Wimal Kapadia
Kepler Cheuvreux
Wolfe Research
AltaCorp Capital
DEUTSCHE BANK	Emmanuel Papadakis
HSBC
Exane BNP Paribas
Bryan, Garnier & Co.
Berenberg Bank
Deutsche Bank Securities
Moody's Investors Service
Dundee
Exane BNP
Bernstein
Argus
Cowen
BRYAN GARNIER	Eric Le Berrigaud
LIBERUM CAPITAL	Graham Doyle
BANK OF AMERICA (BOFA)	Graham Parry

Ratings for Novartis AG

Trading Rating :

Investor Rating :

ESG Refinitiv :

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar